Trailing-twelve-month (TTM) revenue is $6.20 Billion with a year-over-year growth of +5.32%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,512,988,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $1,523,930,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $1,559,619,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $1,599,730,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $6,196,267,000 |
Current P/S: $13,375,093,248 market capitalization ÷ $6,196,267,000 TTM revenue = 2.16x.
Market capitalization source: FMP quote. Quote observed 2026-09-17T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.60B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-18T09:30:33.826Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Annuity Segment | $4,000 | $1,000 | $1,000 | $0 | N/A | N/A |
| Health Segment | $1.1B | $1.2B | $1.3B |
$6.20B
$6.20 Billion
+5.32%
vs. $5.88B a year ago (TTM)
+4.54%
5 Year compound annual growth rate
1 Year
+5.32%
3 Year
+7.13%
5 Year
+4.54%
10 Year
+5.50%
15 Year
+4.10%
20 Year
+3.26%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $6.00B | +$220.56M | +3.82% |
| 2024 | $5.78B | +$330.54M | +6.07% |
| 2023 | $5.45B | +$220.79M | +4.22% |
| 2022 | $5.23B | +$105.39M | +2.06% |
| 2021 | $5.12B | +$382.80M | +8.08% |
| 2020 |
TTM Growth
+5.32%
3-Year CAGR
+7.13%
5-Year CAGR
+4.54%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
| $1.4B |
| $1.5B |
| Investment Segment | $927M | $952M | $987M | N/A | N/A | N/A |
|---|
| Life Segment | $2.7B | $2.9B | $3.0B | $3.1B | $3.3B | $3.4B |
|---|
| $4.74B |
| +$211.02M |
| +4.66% |
| 2019 | $4.53B | +$212.70M | +4.93% |
| 2018 | $4.31B | +$158.83M | +3.82% |
| 2017 | $4.16B | +$221.37M | +5.63% |
| 2016 | $3.93B | +$168.56M | +4.48% |
